Q-omics provides the consensus-scored CPA5 profile across patient tissues and cancer cell-line models. CPA5 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, CPA5 is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, CPA5 RNA expression shows 10,383 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight SKCM, HNSC, and THYM as cancer lineages where CPA5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CPA5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CPA5 survival associations across molecular data types. CPA5 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CPA5 RNA expression–survival associations across cancer types. High CPA5 expression shows unfavorable associations in KIRC, KIRP and ACC, but favorable associations in SKCM, ESCA and BLCA. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for CPA5 RNA expression.
This table summarizes CPA5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for CPA5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CPA5 shows lower tumor expression in KIRP and KICH and higher tumor expression in HNSC, LUAD, BLCA and STAD. The HNSC box plot shows higher CPA5 RNA expression in tumor versus normal tissue (log2 FC = +0.184, t-test p < 0.001).
This table shows molecular features associated with CPA5 in patient tissues and cancer cell lines. In patient samples, CPA5 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, CPA5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in SKIN and SOFT_TISSUE.
